n Cardiovascular Journal of South Africa - Trend towards prolonged survival in bisoprolol-first (Concor®) for heart-failure trial (CIBIS III) : drug trends

Volume 16, Issue 5
  • ISSN : 1680-0745



In the first large prospective study undertaken to contrast the early introduction of beta-blockers in comparison to ACE inhibitors in mild to moderate heart failure, the β selective beta-blocker, bisoprolol (Concor®), administered once daily for six months prior to combined therapy, resulted in a trend towards prolonged survival, although true significance was not reached.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error